Search This Blog

Saturday, July 31, 2021

Evaluation of silver nanoparticles to prevent SARS-CoV-2 infection: in vitro and in vivo


Horacio Almanza-ReyesSandra MorenoIsmael Plascencia-LópezMartha Alvarado-VeraLeslie Patrón-RomeroBelén BorregoAlberto Reyes-EscamillaDaniel Valencia-ManzoAlejandro BrunAlexey PestryakovNina Bogdanchikova

Safety Evaluation of 2nd Dose of mRNA COVID Vaccines in Patients With Immediate Reactions to 1st

 Matthew S. Krantz, MD1Jason H. Kwah, MD, MSCI2Cosby A. Stone Jr, MD, MPH1et al



Allergic reactions after messenger RNA (mRNA) COVID-19 vaccines have been reported to be as high as 2%, with anaphylaxis occurring in up to 2.5 per 10 000 individuals.1 There is uncertainty as to whether to administer a second dose of mRNA COVID-19 vaccine after a first-dose reaction.2,3 In this study, we examine the safety of the second dose of Pfizer-BioNTech or Moderna vaccine in those with a history of immediate and potentially allergic reactions to the first dose.


This multicenter, retrospective study conducted by Massachusetts General Hospital (Boston), Brigham and Women’s Hospital (Boston, Massachusetts), Vanderbilt University Medical Center (Nashville, Tennessee), Yale School of Medicine (New Haven, Connecticut), and University of Texas Southwestern Medical Center (Dallas) from January 1, 2021, to March 31, 2021, included patients with an immediate allergic reaction to the Pfizer-BioNTech or Moderna vaccine, which was defined as: (1) symptom onset within 4 hours of dose 1, (2) at least 1 allergic symptom, and (3) referral for an allergy/immunology consultation with in-clinic or telehealth assessment (eMethods in the Supplement). Anaphylaxis was scored using the Brighton and the National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network criteria.4,5 Confirmed anaphylaxis required meeting at least 1 of these 2 criteria.

The primary outcome was second dose tolerance, which was defined as either: (1) no immediate symptoms after second dose administration or (2) symptoms that were mild, self-limited, and/or resolved with antihistamines alone. For any individuals who did not have their second dose observed by allergy/immunology departments, phone calls elicited clinical details. This study was approved by the Mass General Brigham human research committee with waiver of informed consent.


There were 189 patients who participated in this study (mean [SD] age, 43 (14) years; 163 women [86%]) (Table). Of the mRNA COVID-19 vaccine first-dose reactions evaluated, 130 (69%) were to Moderna and 59 (31%) to Pfizer-BioNTech. The most frequently reported first-dose reactions were flushing or erythema (53 [28%]), dizziness or lightheadedness (49 [26%]), tingling (46 [24%]), throat tightness (41 [22%]), hives (39 [21%]), and wheezing or shortness of breath (39 [21%]). Thirty-two (17%) met anaphylaxis criteria.

A total of 159 patients (84%) received a second dose. Antihistamine premedication before the second dose was given in 47 patients (30%). All 159 patients, including 19 individuals with first-dose anaphylaxis, tolerated the second dose. Thirty-two (20%) reported immediate and potentially allergic symptoms that were associated with the second dose that were self-limited, mild, and/or resolved with antihistamines alone.


This multisite US study supports the safety of Pfizer-BioNTech or Moderna vaccine second dose administration in patients who report immediate and potentially allergic reactions after the first dose. Although mild symptoms were reported in 20% of patients with second dose administration, all patients who received a second dose safely completed their vaccination series and could use mRNA COVID-19 vaccines in the future when indicated. Second dose tolerance following reactions to the first dose argues that either many of these initial reactions are not all truly allergic reactions, or supports an allergic, but non–immunoglobulin E–mediated mechanism in which symptoms can typically be abated with premedications.6

Because the Janssen vaccine received emergency use authorization, the US Centers for Disease Control and Prevention recommended that individuals with an immediate and potentially allergic reaction to the first dose of the Pfizer-BioNTech or Moderna mRNA COVID-19 vaccine could receive a Janssen single dose subsequently.2 However, our data suggest that most patients with immediate and potentially allergic reactions to mRNA COVID-19 vaccines tolerate a second dose. Therefore, it may not be necessary to consider this, to our knowledge, largely unstudied alternative mixed series approach. Although earlier work provided a shared framework for the clinical approach,3 our pooled study was limited by its retrospective study design, referral bias, and lack of a shared evaluation protocol among participating institutions.

COVID-19 Vaccine Safety in Adolescents 12–17 Years — US, Dec 14, 2020–July 16, 2021

 Anne M. Hause, PhD1; Julianne Gee, MPH1; James Baggs, PhD1; Winston E. Abara, MD1; Paige Marquez, MSPH1; Deborah Thompson, MD2; John R. Su, MD, PhD1; Charles Licata, PhD1; Hannah G. Rosenblum, MD1,3; Tanya R. Myers, PhD1; Tom T. Shimabukuro, MD1; David K. Shay, MD

DOI: icon



What is already known about this topic?

In preauthorization trials of the Pfizer-BioNTech COVID-19 vaccine, adolescents aged 12–17 years reported local and systemic mild and moderate reactions. Myocarditis has been observed after vaccination with mRNA vaccines in postauthorization monitoring.

What is added by this report?

Local and systemic reactions after vaccination with Pfizer-BioNTech vaccine were commonly reported by adolescents aged 12–17 years to U.S. vaccine safety monitoring systems, especially after dose 2. A small proportion of these reactions are consistent with myocarditis.

What are the implications for public health practice?

Mild local and systemic reactions are common among adolescents following Pfizer-BioNTech vaccine, and serious adverse events are rare. The Advisory Committee on Immunization Practices conducted a risk-benefit assessment and continues to recommend the Pfizer-BioNTech COVID-19 vaccine for all persons aged ≥12 years.

Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections


Po Ying ChiaSean OngCalvin J ChiewLi Wei AngJean-marc Gilbert ChavatteTze Minn MakLin CuiShirin KalimuddinWan Ni ChiaChee Wah TanLouis Yi Ann ChaiSeow Yen TanShuwei ZhengRaymong Tzer Pin LinLinfa WangYee-Sin LeoVernon J LeeDavid .Chien LyeBarnaby Edward Young